Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Moderate Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $61.5714.

Several equities analysts recently commented on the stock. William Blair assumed coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating on the stock. Stifel Nicolaus upped their price target on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Raymond James Financial restated an “outperform” rating and issued a $63.00 price target (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, September 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Saturday, September 27th.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $34.94 on Friday. The firm has a market capitalization of $1.12 billion, a PE ratio of -10.75 and a beta of 1.58. The company’s 50-day moving average is $28.20 and its 200-day moving average is $22.17. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $40.16.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. BNP Paribas Financial Markets acquired a new stake in Dianthus Therapeutics during the fourth quarter worth about $59,000. Millennium Management LLC grew its stake in Dianthus Therapeutics by 160.2% during the fourth quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock worth $1,972,000 after buying an additional 55,682 shares in the last quarter. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 12.2% during the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company’s stock worth $1,315,000 after buying an additional 6,552 shares in the last quarter. GAMMA Investing LLC grew its stake in Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after buying an additional 3,758 shares in the last quarter. Finally, Moody Aldrich Partners LLC bought a new position in shares of Dianthus Therapeutics in the first quarter worth about $1,349,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.